Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.

J Crohns Colitis · 2020 · PMC6930001 · PMID 31197361

Europe PMC DOI

hedged sentence

0.5850

closest p · 11.7× alpha

0.5850

boldest claim

The sentences

did not reach statistical significancep = 0.585not close (p > 0.1)

In nine out of 13 patients, PDAI scores 4 years after bmMSC treatment were found to be lower than before bmMSC therapy, which however did not reach statistical significance [4.3 vs 3.8, p = 0.585] [ Figure 3A ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.